Australia markets closed

TC Biopharm (Holdings) Plc (TCBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.6000+0.0500 (+3.23%)
At close: 04:00PM EDT
1.7300 +0.13 (+8.12%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5500
Open1.5400
Bid1.6500 x 1400
Ask1.6200 x 1200
Day's range1.5400 - 1.6900
52-week range1.4600 - 88.0000
Volume48,816
Avg. volume1,194,069
Market cap3.741M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-16.2900
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.00
  • PR Newswire

    TC BioPharm Announces Closing of $5.5 Million Public Offering

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the closing of its previously announced public offering of 3,437,500 of its American Depositary Shares (the "ADSs") (or pre-funded warrants in lieu thereof), together with Series C warrants (the "Series C Warrants") to purchase up to 3,437,500 of its ADSs at a public offering price of $1.60 per AD

  • PR Newswire

    TC BioPharm Announces Pricing of $5.5 Million Public Offering

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the pricing of a public offering of 3,437,500 of its American Depositary Shares (the "ADSs") (or pre-funded warrants in lieu thereof), together with Series C warrants (the "Series C Warrants") to purchase up to 3,437,500 of its ADSs at a public offering price of $1.60 per ADS (or pre-funded warran

  • PR Newswire

    TC Biopharm Announces Corporate Restructuring, Reduction in Overhead

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced a corporate restructuring plan to reduce costs and prioritize its pending lead US clinical programs.